CytomX Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of CytomX Therapeutics generated cash of -$56,035,000, which is more than the previous year. Cash used in financing activities reached the amount of $30,230,000 last year. Net change in cash is therefore -$176,479,000.
Cash Flow
| 2014 | 31.80M | -1.66M | 25.55M |
|---|---|---|---|
| 2015 | -27.41M | -130.56M | 153.40M |
| 2016 | -2.03M | 45.85M | 996K |
| 2017 | 170.37M | -121.26M | 23.79M |
| 2018 | -75.52M | 5.92M | 139.62M |
| 2019 | -140.48M | 79.70M | 1.62M |
| 2020 | 5.25M | -18.71M | 16.89M |
| 2021 | -119.03M | 22.48M | 110.21M |
| 2022 | -110.78M | 98.26M | 648K |
| 2023 | -56.03M | -150.67M | 30.23M |
CTMX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 194.56M | 206.44M | 192.77M | 189.34M | 248.49M | 178.46M | 104.64M | 59.82M | 64.39M | 8.70M |
Operating activities | ||||||||||
Net income | -569K | -99.31M | -83.60M | -32.88M | -102.23M | -84.60M | -43.09M | -58.9M | -35.37M | -30.31M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 2.17M | 2.44M | 2.70M | 2.57M | 2.60M | 1.88M | 1.64M | 1.73M | 1.20M | 783K |
Stock-based compensation expense | 8.55M | 13.12M | 13.16M | 14.78M | 19.1M | 0 | 11.28M | 10.09M | 3.98M | 553K |
| Deferred income tax benefit | 8.55M | 13.12M | 13.16M | 14.78M | 19.1M | 0 | 11.28M | 10.09M | 3.98M | 553K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 32.55M | -35.19M | 8K | -785K | 84K | 10.04M | -7.82M | -1.56M | 1.13M | -1.63M |
Inventories | 0 | 0 | 11.64M | -11.11M | -11.29M | 19.91M | 10.31M | -253K | 1.80M | 188K |
Accounts payable | -1.42M | 68K | -139K | -857K | -374K | 261K | -2.44M | 1.76M | 2.94M | 660K |
Cash generated by operating activities | -56.03M | -110.78M | -119.03M | 5.25M | -140.48M | -75.52M | 170.37M | -2.03M | -27.41M | 31.80M |
Investing activities | ||||||||||
Purchases Of Investments | -424.83M | 0 | -99.89M | -199.10M | -174.99M | -204.60M | -218.70M | -121.51M | -250.90M | 0 |
Investments In Property Plant And Equipment | -840K | -1.74M | -1.60M | -2.30M | -3.49M | -3.78M | -1.55M | -2.17M | -1.59M | -1.66M |
Acquisitions Net | 0 | 0 | -24.09M | 16.40M | -83.19M | -5.92M | 121.26M | 52K | 0 | 0 |
Cash generated by investing activities | -150.67M | 98.26M | 22.48M | -18.71M | 79.70M | 5.92M | -121.26M | 45.85M | -130.56M | -1.66M |
Financing activities | ||||||||||
Common Stock Issued | 30.23M | 648K | 107.71M | 11.28M | 1.60M | 134.59M | 19.95M | 159K | 81.77M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6.70M | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -78K | -3.06M | -1.25M |
Cash used in financing activities | 30.23M | 648K | 110.21M | 16.89M | 1.62M | 139.62M | 23.79M | 996K | 153.40M | 25.55M |
Net Change In Cash | -176.47M | -11.88M | 13.67M | 3.43M | -59.15M | 70.02M | 72.90M | 44.82M | -4.57M | 55.69M |
Cash at end of period | 18.08M | 194.56M | 206.44M | 192.77M | 189.34M | 248.49M | 177.54M | 104.64M | 59.82M | 64.39M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |